Find a Clinical Trial

The Epilepsy Foundation’s Clinical Trials Portal connects participants to current trials and observational studies to help accelerate development and testing of new treatments.

In this video, the Epilepsy Foundation’s Chief Scientific Officer Dr. Jacqueline French introduces one of her patients, Sally. You'll hear Sally and her family share their experience participating in a clinical trial similar to the ones listed below. Watch the video, then scroll down to find some trials that are recruiting or to search for another trial that’s right for you.

The Epilepsy Foundation helps drive clinical trial recruitment. A 2015 study showed we brought over 300 contacts to the Epilepsy Phenome/Genome Project.

Search for Clinical Trial

Select any filter and click on Apply to see results

Clinical Trials Actively Recruiting

The following are studies that are currently searching for participants.
Please contact the research study staff directly for the most current information.

XEN1101 as Adjunctive  Therapy in Focal-onset Epilepsy, with an  Open-Label  Extension

Do you still experience seizures despite taking medications for your focal-onset epilepsy? Xenon Pharmaceuticals Inc. is enrolling adults with focal-onset epilepsy into a clinical trial for XEN1101, a novel investigational anti-seizure medication. The study drug is taken once a day and study subjects will continue taking their prescribed epilepsy medications during the trial.

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE)

This study is looking at the safety and efficacy of MRI-guided laser ablation therapy with Visualase™ (laser ablation may also be called laser interstitial thermal therapy or LITT) for seizures coming from the temporal lobe in people who are taking seizure medicines.

Perampanel Study for Infants with Epilepsy

This clinical research study is being done to learn more about the safety of Perampanel (E2007), the study drug, and how well it's tolerated in infants, from 1 month to less than 24 months old (<2 years), who have epilepsy.

Cannabidiol as an Add-on Therapy in Tuberous Sclerosis Complex

This study is looking at how effective and safe cannabidiol (also known as CBD) is in people 1 year to 65 years old living with Tuberous Sclerosis Complex (TSC). In this study, CBD would be given in addition to their current anti-seizure medications.

Epilepsy Foundation’s Human Epilepsy Project (HEP2): Resistant Focal Seizures Study

The HEP2 study will follow 200 people with medication-resistant focal epilepsy (with seizures that occur at least 2 times per month) over two years to measure changes in their seizure frequency, treatments used, adverse events experienced, presence of comorbidities like depression and anxiety, healthcare costs, and quality of life.

Effectiveness of Inhaled Staccato Alprazolam in Treating an Episode of Focal or Generalized Seizure

Are you an adult living with focal or generalized epilepsy? A new clinical trial is looking at how effective and safe orally-inhaled alprazolam (also known as STAP-001) is in people 18 years of age or older with focal or generalized epilepsy when given at the time of a seizure episode. This study is commonly referred to as StATES (Staccato Alprazolam Terminates Epilepsy Seizures).

Eslicarbazepine Acetate (ESL) as First or Later Add-On Therapy for the Treatment of Partial-Onset Seizures

This study is looking at how effective and safe eslicarbazepine acetate (also known as ESL) is in people 18 years of age or older with partial-onset (focal) seizures, when it is added to their current anti-seizure medication(s).

PFIZER A0081096: Looking for Changes in Eyesight from Using Pregabalin

This three month study will look at people between 18-65 years old, taking their own anti-seizure medications in addition to either the study drug (Pregabalin) or a placebo. The aim is to look for changes in eyesight.

All of Us Research Program

The All of Us Research Program is an effort to gather data from one million or more people living in the United States to accelerate research and improve health. The program will be open to people both healthy and sick, from all communities.

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

This Phase IIb trial will test whether earlier treatment versus standard treatment with vigabatrin in infants with tuberous sclerosis complex (TSC) will have a positive impact on developmental outcomes at 24 months of age. It also tests whether early treatment prevents or lowers the risk of developing infantile spasms and refractory seizures. It is a randomized, double-blind, placebo-controlled clinical trial design. Infants under the age of 6 months diagnosed with TSC but without history of seizures or infantile spasms may be eligible.

Focused Ultrasound for Treatment of Epilepsy

The University of Virginia Comprehensive Epilepsy Program is conducting a research study on the use of focused ultrasound to treat deep lesions in the brain causing intractable epilepsy in adults 18 to 80 years old. The study will evaluate the effectiveness and safety of an investigational device that uses ultrasound or sound waves from outside the head to treat seizures that are not well controlled by medication and are due to a small growth of abnormal cells in the middle of the brain, most commonly hypothalamic hamartomas.

Clinical Trials and Studies in Follow-Up

The Human Epilepsy Project (HEP)

This project will look at individuals in the early stages of treatment for focal epilepsy to study treatment responses and the likelihood of developing drug resistant epilepsy. Using this information, HEP hopes to discover biomarkers that will predict how people with focal seizures respond to treatment.

MONEAD: Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure

Epilepsy is one of the most common neurological disorders affecting women of childbearing age. Poor pregnancy outcomes are increased in these women and their children. The MONEAD study will increase our knowledge on multiple levels to improve care and reduce negative outcomes in these mothers and children. An overall goal of this study is to establish the relationship between antiepileptic drug exposure and outcomes in the mother and child. An additional goal is to describe and explain the variability in antiepileptic drug exposure and response.

  • For more information about this trial, see Identifier: NCT01730170

Completed Clinical Trials and Studies

Rare Epilepsy Network

The Rare Epilepsy Network (REN) is a partnership between rare epilepsy organizations, the Epilepsy Foundation, Columbia University, and Research Triangle International to conduct research to improve outcomes of rare conditions associated with epilepsy and seizures.

The original REN survey is no longer actively enrolling. REN data is available for research request and a dashboard previewing a subset of data collected is now viewable.

Established Status Epilepticus Treatment Trial (ESETT)

A medical research study to learn how to treat patients with a type of prolonged seizures in the emergency department was recently performed in this community at The University of Maryland Medical Center in Baltimore.

Before the study, doctors didn’t know what medicine worked best. The study showed that three medicines commonly used to treat prolonged seizures all work similarly well, stopping seizures about half the time in both children and adults. The medicines were also similar in safety. These results give doctors more flexibility and confidence when treating patients with prolonged seizures.

The researchers thank the community for their support of this emergency research conducted with exception from consent. The study, called the Established Status Epilepticus Treatment Trial, or ESETT, was published in the November 28, 2019 issue of the New England Journal of Medicine. The study was funded by the National Institutes of Health.

To learn more about the research and the results, visit the ESETT website at You can contact the primary study coordinator Virginia Ganley, RN with any questions at 410‐328‐6395 or email

Epilepsy Genetics Initiative (EGI)

The Epilepsy Genetics Initiative (EGI) was created by Citizens United for Research in Epilepsy (CURE) to bridge the gap between people with epilepsy, clinicians, and researchers and tailor advances in medical care and decision-making to individual patients. The EGI has created a centralized database to hold and analyze the genetic data of people with epilepsy.

Fenfluramine Assessment in Rare Epilepsy (FAiRE): ZX008-Study 2/1504

The FAiRE program of clinical trials is exploring whether an investigational drug (ZX008) can improve seizure control in children and young adults with Dravet syndrome. FAiRE stands for “Fenfluramine Assessment in Rare Epilepsy.” The goal of the ZX008-Study 2/1504 trials is to show that ZX008 is a safe and effective treatment for children and adolescents with Dravet syndrome when added on to their other seizure medications.

ROSE (Radiosurgery or Open Surgery for Epilepsy)

Epilepsy surgery is an alternative for some people whose seizures cannot be controlled by anticonvulsant medications. Radiosurgery is a minimally-invasive radiation procedure used to treat tumors and other abnormalities of the brain, and is currently being investigated as an alternative to open surgery treatment for a very select group of patients with medically refractory partial epilepsy. The Gamma Knife® radiosurgery instrument used in this study uses tightly focused beams of radiation to injure the surgical target, rather than removing it with open surgery. Gamma Knife radiosurgery does not require an inpatient hospital stay. This trial, sponsored by the National Institutes of Health and Elekta, the company that manufactures the Gamma Knife, was designed to compare advantages and disadvantages of open surgery versus radiosurgery. The ROSE Trial (Radiosurgery or Open Surgery for Epilepsy) is in follow-up phase at major epilepsy centers across the US and Canada.

  • For more information about this trial, see Identifier: NCT00860145

The Epilepsy Phenome/Genome Project (EPGP)

EPGP is a large-scale, international, multi-institutional, collaborative research project aimed at advancing the understanding of the genetic basis of the most common forms of epilepsy. The overall goal of EPGP was to collect detailed, high quality phenotypic (i.e., characteristics of individuals, from the molecular level to the whole person) information on persons with epilepsy and to compare the phenotypic information with genomic information. EPGP provides a resource that may lead to many discoveries related to the diagnosis and treatment of epilepsy, including the eventual development of new therapies based on a better understanding of causes of the disorder.

  • For more information about this trial, see Identifier: NCT00552045

Important note about the Portal

This Clinical Trial Portal includes all studies for which study sponsors have requested inclusion and which meet the Epilepsy Foundation's inclusion criteria. In addition, some sponsors whose studies have been accepted for inclusion in the portal have made a payment to the Epilepsy Foundation in order to receive the Foundation's additional assistance in promoting the study, in order to facilitate patient enrollment. The decision to participate in a particular study should only be made after thorough review of all available study materials, including the relevant study protocol, and discussion with the patient's physician.

    Provides regularly updated information about federally and privately supported clinical research in human volunteers.
  • National Institutes of Health (NIH)
    Search the collection of research studies being conducted at the NIH Clinical Center.
  • About Clinical Research
    Learn how experimental drugs are tested, who pays for the research and how to participate in clinical trials.
  • Approved Drugs
    Find out which medications have been approved by the FDA.
  • Clinical Trial Results
    Find easy access to information about the results of recently completed and ongoing clinical trials.

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

24/7 helpline